AzTrials
AzTrials

Percutaneous Large Hole Vascular ClosureNCT05163548

PerQseal®+ Early Feasibility Study

A study testing PerQseal Plus Device in people with Percutaneous Large Hole Vascular Closure, run by Vivasure Medical Limited at 5 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of this Early Feasibility Study (EFS) is to evaluate the initial safety and preliminary effectiveness of the PerQseal®+ VCD in a small number of subjects when used to achieve hemostasis of common femoral arteriotomies created by 14 to 22 F sheaths (arteriotomy up to 26 F) in subjects undergoing… Read more about this study

Who is it for?
Ages 19 years and older
Conditions the study is for
Percutaneous Large Hole Vascular Closure
What is being tested?
PerQseal Plus Device
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
15 participants
Where
5 sitesUnited States
Study dates
8 Mar 2022to 7 Jul 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 1. Age ≥ 19 years, 2. Clinically indicated for a large bore interventional transcatheter procedure, e.g., transcatheter aortic valve repair (TAVR) or endovascular abdominal aortic aneurysm repair (EVAR), or thoracic endovascular aneurysm repair (TEVAR) using a percutaneous common femoral arteriotomy created by a 14 to 22 F sheath, 3. Subject is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements, 4. Females who are not pregnant or lactating and not planning to become pregnant for the duration of the study.
  • -

Who cannot join

  • Baseline Exclusion Criteria 1. Evidence of systemic bacterial or cutaneous infection, including groin infection Baseline Exclusion Criteria
  • Evidence of systemic bacterial or cutaneous infection, including groin infection,
  • Known bleeding diathesis, definite or potential coagulopathy, platelet count < 100,000/µl or subjects on long term anticoagulants with an INR > 2 within 12 hours prior to index procedure,
  • Significant anemia (hemoglobin < 9 g/dL or hematocrit < 27%), within 24 hours prior to index procedure,
  • Known type II heparin-induced thrombocytopenia,
  • NYHA functional class IV heart failure that is uncontrolled and requires treatment in the Intensive Care Unit, within 24 hours prior to primary procedure,
Show all 42Show fewer
  • Documented left ventricular ejection fraction < 20%,
  • Unilateral or bilateral lower extremity amputation.
  • Claudication (e.g., Rutherford category 3 or greater), documented untreated iliac or common femoral artery diameter stenosis > 50% or previous bypass surgery/stent placement in the common femoral artery of target leg,
  • Known existing nerve damage in the target leg,
  • Renal insufficiency (Glomerular Filtration Rate ≤ 30 ml/min or baseline serum creatinine > 2.5 mg/dL) or on renal replacement therapy,
  • Known allergy to any of the materials used in the PerQseal®+ device (refer to Instructions for Use),
  • Subject unsuitable for surgical repair of the target leg access site,
  • Subject has undergone a percutaneous procedure greater than 8 F sheath in the target leg, within the 90 days prior to index procedure,
  • Subject has undergone use of an intra-aortic balloon pump through the target leg access site within 90 days prior to the index procedure,
  • Subject has undergone a percutaneous procedure of 8 F sheath or less using an absorbable intravascular closure device for hemostasis, in the target vessel, within the 90 days prior to index procedure,
  • Subject has undergone a percutaneous procedure of 8 F sheath or less using a suture mediated closure device or manual/mechanical pressure for hemostasis in the target leg, within the 30 days prior to index procedure,
  • Evidence of marked tortuosity of the femoral or external iliac artery in the target leg, based on pre-primary procedure CT angiography,
  • Evidence of arterial diameter stenosis > 30% within 15 mm proximal or distal to arteriotomy site based on pre-primary procedure CT angiography,
  • Evidence of anterior wall calcification of the target common femoral artery (other than small, diffuse deposits which in the opinion of the investigator will not impede the vascular closure procedure) within 15 mm proximal or distal to arteriotomy site based on pre-primary procedure CT angiography,
  • Target femoral artery diameter is less than 7 mm in diameter, based on pre-primary procedure CT angiography,
  • Further planned endovascular procedure in the target leg in the 30 days following the index procedure,
  • Subject is enrolled in another investigational medical device or drug study
  • Subject has been previously enrolled in this clinical study.
  • Current COVID-19 infection (with or without symptoms), recent positive test for COVID-19, or recent exposure (within two weeks) to a person with COVID-19 infection.
  • Procedural Exclusion Criteria If any Procedural Exclusion Criteria listed below, then closure with PerQseal®+ device is not permitted.
  • Initial common femoral arterial access achieved with manual palpation or blind arterial stick access, without use of an image guided approach (ultrasound or angiography).
  • Difficult dilation during initial target femoral artery access (e.g., that damages or kinks sheath dilators) while step-dilating up to the large-bore device,
  • During arterial puncture, the target femoral artery suspected to have experienced a back arterial wall needle puncture or underwent > one needle puncture during the primary procedure.
  • Subject has a tissue tract (i.e., estimated distance from skin entry point to arterial anterior surface at arteriotomy) expected to be greater than 8 cm,
  • Significant blood loss requiring transfusion of blood products during primary procedure or within 30 days prior to index procedure,
  • Activated clotting time (ACT) > 300 seconds immediately prior to sheath removal or if ACT measurements are expected to be > 300 seconds for more than 24 hours after index procedure,
  • Target puncture site is in a vascular graft,
  • Target arteriotomy greater than 26 F,
  • Target arteriotomy in the profunda femoris or superficial femoral artery or is in common femoral artery, but within 15 mm proximal of the bifurcation of the superficial femoral/ profunda femoris artery,
  • Target arteriotomy located at the level or above the inferior epigastric artery and/or beneath or above the inguinal ligament based on bony landmarks (above femoral head on A-P projection),
  • Subjects with an acute hematoma > 4 cm diameter, arteriovenous fistula, pseudoaneurysm, or intraluminal thrombosis at the target access site identified intra-procedurally,
  • Evidence of bleeding around the primary procedure sheath (BARC type 2 or higher),
  • Intra-procedural angiographic evidence of arterial laceration, dissection or stenosis within the femoral artery that would preclude use of the PerQseal®+ device,
  • Uncontrolled hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg) at the time of planned vascular closure,
  • Systolic blood pressure < 90 mmHg at the time of planned vascular closure.
  • -

Trial locations and contacts

5 sites in 1 country.

5 sites in 1 country

United States5 sites

  • Weill Cornell Medicine

    New York, New York, 10021

  • The Valley Hospital

    Ridgewood, New Jersey, 07450

  • Stony Brook University Hospital

    Stony Brook, New York, 11794

  • Montefiore Hospital

    The Bronx, New York, 10467

  • Lankenau Heart Institute

    Wynnewood, Pennsylvania, 10032

Other trials in United States

About this study

Official title: Early Feasibility Study of the Vivasure PerQseal®+ (PerQseal® Plus) Vascular Closure Device When Used to Achieve Hemostasis of Common Femoral Arteriotomies Created by 14 to 22 F Sheaths in Patients Undergoing Percutaneous Transcatheter Procedures

The objective of this Early Feasibility Study (EFS) is to evaluate the initial safety and preliminary effectiveness of the PerQseal®+ VCD in a small number of subjects when used to achieve hemostasis of common femoral arteriotomies created by 14 to 22 F sheaths (arteriotomy up to 26 F) in subjects undergoing Percutaneous Transcatheter procedures.

Read the detailed description

This study is a prospective, multi-center, single arm EFS. Patients undergoing a percutaneous trancatheter procedure, requiring an arteriotomy created by 14 - 22 F sheaths (arteriotomies up to approx. 26 F), via the common femoral artery will be screened against the study inclusion/exclusion criteria. If the patient meets study eligibility requirements, they shall be invited to participate, provide informed consent, and shall subsequently be assigned a study ID number. Enrollment will occur at the point where the PerQseal®+ VCD study device first enters the patient's body.

The planned enrollment is 15 treated patients at a maximum of 5 study sites (minimum of 3) located in the United States.

Being tested
PerQseal Plus Device
Keywords
vascular closure, vascular closure device, large hole percutaneous closure, large bore percutaneous closure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PerQseal Plus DeviceDevice

    Also called Vascular Closure Device

    Percutaneous closure of femoral artery access site created by 14 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing Percutaneous Transcatheter procedures.

Study groups in NCT05163548
Study groupRoleWhat they receive
Subjects that receive PerQseal Plus DeviceExperimentalSubjects undergoing large hole endovascular percutaneous procedures with a femoral arteriotomy created with 14 to 22 F sheaths (arteriotomy up to 26 F)
Receives: Device: PerQseal Plus Device

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Safety: Major Access Site Complications

    The primary safety endpoint is the rate of major access site complications attributable to the PerQseal® device. As per FDA definitions for Major access site complications.

    Measured: though 30 days

  2. Efficacy: Time to Haemostasis

    Elapsed time in minutes from PerQseal® Introducer sheath removal to first observed cessation of common femoral artery (CFA) bleeding (excluding cutaneous or subcutaneous oozing, and in the absence of a developing hematoma).

    Measured: 20 minutes

Secondary outcomes (6)

  1. Safety: Incidence of Minor Access Site Complications

    Incidence and severity of minor access site complications attributable to the PerQseal® device, adapted from FDA-provided definitions.

    Measured: through 30 days

  2. Efficacy: PerQseal® Device Technical Success Rate

    PerQseal® Device Technical Success Rate, defined as the number of PerQseal® devices that are deployed and achieve hemostasis (i.e., cessation of bleeding (excluding cutaneous or subcutaneous oozing)) without need for firm, adjunctive manual compression for greater than 10 minutes or alternative treatment (other than adjunctive endovascular ballooning) at target access site, divided by the total number of PerQseal® devices where deployment was attempted.

    Measured: 10 minutes

  3. Efficacy: PerQseal® Treatment Success Rate

    PerQseal® Treatment Success Rate, defined as the number of subjects who meet PerQseal® Device Technical Success without experiencing a Major Access Site Complication, divided by the total number of subjects where PerQseal® device deployment was attempted.

    Measured: through 30 days

  4. Efficacy: Time to Device Deployment

    Time to Device Deployment, defined as the time from insertion of the PerQseal® device into the PerQseal Introducer sheath to complete removal of the PerQseal® device delivery system and PerQseal® Introducer sheath from the subject following PerQseal® deployment.

    Measured: 20 minutes

  5. Efficacy: Time to Ambulation

    Time to Ambulation is defined as: the elapsed time from PerQseal® + removal until the subject can walk 20 feet without re-bleeding at the target access site. This endpoint will be evaluated only for subjects who are ambulatory at the point of enrollment.

    Measured: through 5 day

  6. Efficacy: Total Closure Time

    Total Closure Time is defined as: Time to Hemostasis (TTH) plus Time to Device Deployment

    Measured: 40 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Dec 2021
  2. Study start8 Mar 2022
  3. Primary completion7 Jul 2022
  4. Study completion7 Jul 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Early Feasibility Study
Masking
None (open label)
Enrolment
15 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05163548
Sponsor's protocol ID
P856-00
Status last verified
Apr 2023
First submitted
6 Dec 2021
Last updated
26 Apr 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing PerQseal Plus Device in people with Percutaneous Large Hole Vascular Closure, run by Vivasure Medical Limited at 5 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 42 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Safety: Major Access Site Complications (time frame: though 30 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05163548.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Apr 2023.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in